Navigation Links
RiboMed Receives Three Additional Patents for Disease Diagnostics Methods

CARLSBAD, Calif., Dec. 10, 2012 /PRNewswire-iReach/ -- RiboMed Biotechnologies Inc., a leading Epigenetics-Based Diagnostics company, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for three additional patents covering the use of their core technology, Abscription® (Abortive Transcription), for disease and biowarfare agent related biomarker detection.  The patents expand protection to MethylMagnet® and MethylMeter®, RiboMed's bisulfite-free DNA methylation detection products and assays, including a new prognostic test for brain cancer, G-CIMP DecisionDx.

"These patent issuances further solidify RiboMed's position in clinical diagnostics, particularly in the use of DNA Methylation biomarkers for cancer detection, staging and drug development" stated Dr. Michelle Hanna, Chief Executive Officer and Scientific Director of RiboMed.  "The technologies protected by these patents make DNA methylation profiling possible even on formalin fixed paraffin embedded (FFPE) tumor tissues, as we have shown with the G-CIMP DecisionDx test launched in RiboMed's CLIA laboratory earlier this year in partnership with Castle Biosciences." G-CIMP stands for Glioma specific CpG Island Methylator Phenotype, and the test predicts the aggressiveness of certain brain tumors, providing physicians and patients with a new tool for making treatment decisions.

The claims of U.S. Patent 8,263,339, entitled "Abscription based molecular detection" broadly cover RiboMed's core Abscription technology for use in detecting a wide variety of molecular biomarkers, including DNA, RNA, protein and methylated DNA. Detection tests reduced to practice in addition to those for DNA methylation include sensitive and robust assays for Salmonella (DNA), viral RNAs and toxic proteins, such as ricin, Botulinum toxin and the common food poisoning agent, SEB. These assays were developed with the Departments of Defense (DARPA) and Homeland Security (HSARPA).

U.S. Patent 8,242,243, entitled "Methods and reagents for detecting CpG methylation with a methyl CpG binding protein (MBP)" covers a highly quantitative and sensitive, bisulfite-free method for measuring DNA methylation at CpG sites and CpG islands using RiboMed's proprietary Methyl CpG binding fusion protein. This work was supported in part by Small Business Innovative Research grant and contract awards from the National Cancer Institute.  In addition to the currently available brain cancer staging test, RiboMed is developing similar DNA methylation profile based diagnostic, prognostic and companion diagnostic tests for ovarian and lung cancers.

Finally, U.S. Patent 8,211,644, entitled "Molecular beacon based methods for detection of targets using Abscription" provides claims to sensitive fluorescence-based methods using molecular beacons to detect the products of Abscription and makes real time detection methods possible. The molecular beacon-based technology makes Abscription more attractive to the vast majority of clinical and research laboratories that do not have access to a mass spectrometer, which is used for the current G-CIMP assay, but routinely use fluorescence detection instruments.  The molecular beacon format allows for more streamlined workflows and faster assay set-up.  The new fluorescence read-out is readily adapted for the detection of RNA, DNA and protein targets and should have wide applicability in areas such as cancer diagnostics and environmental testing.

About RiboMed Biotechnologies, Inc.

RiboMed Biotechnologies, Inc. ( is a molecular diagnostic company providing proprietary epigenetic and genetic biomarker tests for applications in Personalized Medicine and Companion Diagnostics, which is the use of information about an individual's cellular biomarkers to detect and treat disease. The current focus of the Company is on the detection of epigenetic biomarkers (DNA methylation) and genetic biomarkers associated with disease initiation, progression and response to drug treatment. 

RiboMed provides products and services for disease management and drug development utilizing its proprietary and patented technologies for biomarker detection (Abscription®) and methylated DNA isolation and quantification (MethylMagnet® and MethylMeter®). In February, 2011, the Company expanded to add the RiboMed Clinical Services Laboratory (RCSL, CLIA License #05D2020043).

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of RiboMed and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the Company's control, and may turn out to be materially different. RiboMed expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation.

Media Contact: Michelle Hanna, CEO & Scientific Director, RiboMed Biotechnologies, Inc., 760-448-1355,

News distributed by PR Newswire iReach:

SOURCE RiboMed Biotechnologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. RiboMed Receives Three Additional Patents for Disease Diagnostics Methods
2. UCSB professor receives award for graphene electronics research
3. Watsons Generic Yaz(R) Receives FDA Approval
4. Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin
5. Life Technologies Ion Personal Genome Machine Receives San Diegos CONNECT Most Innovative New Product Award
6. MacroGenics Receives Milestone Payment as Part of Its Global DARTâ„¢ Alliance with Boehringer Ingelheim
7. Intimate Bridge 2 Conception, Inc. Receives $4.3M
8. Pacific Meso Center Receives Generous Donation to First Free-Standing Mesothelioma Research Laboratory in Los Angeles
9. BioNeutral Group Receives $400,000 in Equity Financing
10. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
11. Arcion Receives Notice of Allowance for US Patent for Novel Topical Lidocaine Formulation for Pain
Post Your Comments:
(Date:11/24/2015)... SAN DIEGO , Nov. 24, 2015 Halozyme Therapeutics, ... Jaffray Healthcare Conference in New York on ... Dr. Helen Torley , president and CEO, will provide a ... New York at 1:00 p.m. ET/10:00 a.m. ... communication and investor relations, will provide a corporate overview. --> ...
(Date:11/24/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) ... of the Toronto Stock Exchange, confirms that as of ... corporate developments that would cause the recent movements in ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged ...
(Date:11/24/2015)... ... 24, 2015 , ... The Academy of Model Aeronautics (AMA), led by its ... as Multirotor Grand Prix, to represent the First–Person View (FPV) racing community. , FPV ... embraced this type of racing and several new model aviation pilots have joined the ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris ... today that the remaining 11,000 post-share consolidation (or ... Warrants (the "Series B Warrants") subject to the ... on November 23, 2015, which will result in ... giving effect to the issuance of such shares, ...
Breaking Biology Technology:
(Date:10/29/2015)... , Oct. 29, 2015 Today, ... announced a partnership with 2XU, a global leader ... deliver a smart hat with advanced bio-sensing technology. ... other athletes to monitor key biometrics to improve ... strategic partnership, the two companies will bring together the ...
(Date:10/27/2015)... BERLIN, Germany , October 27, 2015 ... 2015. SMI,s Automated Semantic Gaze Mapping technology (ASGM) automatically ... SMI,s Eye Tracking Glasses , so that ... Suite BeGaze. --> Munich, Germany ... technology (ASGM) automatically maps data from mobile eye tracking ...
(Date:10/26/2015)... , October 26, 2015 /PRNewswire/ ... --> adds Biometrics ... to 2021 as well as Emerging ... research reports to its collection of ... . --> ...
Breaking Biology News(10 mins):